Putting the emphasis on Authenticity. European Medicines Agency (EMA) recognized Chios Mastic as a medicine of herbal origin at the meeting that took place in London, on August 7 2015. The decision was unanimous and Chios Mastic was accepted to be included in the category of traditional herbal medicines. IASIS PHARMA played a pivotal role in the recognition of Chios Mastic both at European [...]
IASIS PHARMA and its subsidiary company Pharma Q, Chios Mastiha Growers Association and its subsidiary Mediterra, and Pharmagnose, the spin-off company of the Faculty of Pharmacy - University of Athens, join forces setting Greek nature as a focal point, by establishing the unique Chios Mastiha Research & Development Center. Manufactured with pharmaceutical industry standards, the [...]
The first meeting of the research program under the distinct title “EXANDAS” of the Marie Sklodowska Curie Actions (MSCA) program successfully took place on 21-22 April 2017. The program aims to exploit the aromatic plants’ by-products, Chios Mastic included, for the purpose of developing novel pharmaceutical products. The program’s coordinator is Assistant Prof. N. Aligiannis, [...]
IASIS PHARMA proudly announces the exclusive sponsorship of a clinical trial on the effect of Chios Mastic on blood vessels’ functionality and inflammation”. The research center conducting the study is “Alexandra” General Hospital, the results of the study are expected to be announced the last quarter of 2016.
IASIS PHARMA proudly announces the exclusive sponsorship of a clinical trial on the effect of Chios Mastic in capsules on Helicobacter Pylori. The main research center is “Laiko” Hospital of Athens. Read more about the study's latest findings here
ATHENS, 01-02/04/2016 The kick-off meeting of the research program under the distinct title “EXANDAS” of the Marie Sklodowska Curie Actions (MSCA) programs was successfully organized on 1-2 April 2016. The specific program aims to exploit the aromatic plants’ by-products such as the Chios Mastic for the purpose of developing novel pharmaceutical products. The meeting took place [...]
BRUSSELS, 10/11/2015 IASIS PHARMA proudly announces its participation in a program of H2020. The program Horizon 2020 is the financing framework of the EU for research and Innovation that will cover the period 2014-2020, with a budget of approximately 80 billion Euros. The program supports the strategy "Europe 2020" that promotes research and innovation as the [...]
IASIS PHARMA has a key role in the establishment of Chios Mastiha in Europe as well as globally as a unique herbal product with a wide range of beneficial but mainly therapeutic indications. in August 2015, European Medicines Association (EMA) unanimously decided to include Chios Mastiha in the category of traditional herbal medicines. Read more [...]
Our vision for a healthier world is always and absolutely connected with the environment. We respect Greek nature, learning from it and using the presents that kindly offers us. Thus, we are also able to create unique, natural compositions for the benefit of health. IASIS PHARMA contribution to the worldwide recognition of Chios Mastic as [...]
We do not rest in only meeting our legal obligations for environmental protection. Despite the fact that IASIS PHARMA production methods are environmentally friendly, we are constantly investing in new technologies and carry out continuous checks. With targeted moves: We improve our production lines not only in terms of their efficiency, but also in the management [...]
